Patient undergoing cardiovascular check-up. The risk of death from any cause was higher with degarelix. Degarelix did not reduce the risk of major adverse cardiovascular events (MACE) when compared ...

ORLANDO—Prostate cancer (PCa) patients treated with degarelix have a lower risk of PSA failure or death compared with those treated with leuprolide, according to the findings of a long-term study. The ...

Degarelix is a new hormonal therapy from the GnRH receptor blocker class of agents that immediately blocks the GnRH receptor and achieves fast testosterone suppression without an initial surge. In the ...

ORLANDO -- PSA progression slowed significantly in prostate cancer patients switched to degarelix (Firmagon) after 12 months of leuprolide therapy, data from an open-label extension study showed. The ...

BETHESDA, Md., Dec. 4 Drs. Neal Shore and E. David Crawford presented results for prostate-specific antigen (PSA) recurrence from the additional analysis of secondary end points of biochemical ...

On-target activity of neoadjuvant cixutumumab and combined androgen deprivation therapy for high-risk prostate cancer: A phase II trial. Background: Degarelix, a GnRH receptor antagonist inducing ...

Ferring Pharmaceuticals, USA today received approval from the U.S. Food and Drug Administration (FDA) for degarelix, a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist, ...

Circulating tumor cells (CTCs) as a predictor of metastatic disease in patients with biochemical recurrence (BR) of prostate cancer with equivocal scan results. Background: Degarelix, is a ...

Review the side-effects of Degarelix as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

The U.S. Department of Veterans Affairs (VA) has begun a clinical trial of a potential coronavirus treatment for men, utilizing a drug typically used to treat advanced prostate cancer. The drug ...

A leading cancer surgeon has described Ferring's new prostate cancer drug degarelix, as a "breakthrough" on the basis of fresh Phase III results. A leading cancer surgeon has described Ferring’s new ...

*Localized: T 1/2, NX or N0, and M0. ‡ Locally advanced: T3/4, NX or N0, and M0, or N1 and M0. ITT: Intention to treat; PSA: Prostate-specific antigen. Reproduced ...